Executive Summary
15 bullish contract option exercises totaling $4.27B in obligations signal robust federal demand for defense/IT, health R&D, construction, and remediation services, with multi-year visibility through 2041. Leidos entities capture 29% ($1.27B) across aviation, biomed, and engineering, underscoring backlog strength for LDOS. Unexercised options exceed $2B potential, favoring contractors with execution track records amid firm-fixed-price and cost-plus structures.
Tracking the trend? Catch up on the prior Contract Option Exercises digest from February 06, 2026.
Investment Signals(3)
- Leidos dominates with $1.27B multi-agency wins(HIGH)▲
Three contracts (ERAM/ERIDS, NCI tasks, Hickam AFB engineering) total $1.27B obligation, base+options $7.7B, providing 20-year revenue stability.
- Construction firms secure $800M+ infrastructure backlog(HIGH)▲
Brasfield & Gorrie ($382M), HCBeck ($221M), Stronghold ($217M) win ports, CDC, NPS projects with 85%+ average outlay progress.
- Small/mid-caps gain $1.8B in IT/remediation/defense(MEDIUM)▲
Kratos S2 ($338M SBIR), Remote Medicine ($484M HIV kits), North Wind ($171M DOE remediation), Alvarez ($130M VA LAN) show validated capabilities with 60%+ outlays.
Risk Flags(3)
- Execution[HIGH RISK]▼
Firm-fixed-price structures across 60% of contracts ($2.6B) expose to cost overruns in construction/remediation amid 3-20 year terms.
- Execution[MEDIUM RISK]▼
Subaward dependencies average 25% of obligations (e.g., $275M/439 for Kratos, $82M/191 for Leidos GSA), risking delays.
- Market[MEDIUM RISK]▼
Zero/low outlays in new awards (HII $0, Leidos Biomed $24M, Brasfield PBS $0) signal funding delays.
Opportunities(3)
- ◆
$2B+ unexercised options (e.g., HII $860M, Leidos ERAM $6B ceiling, Alvarez $101M) across 80% of records.
- ◆
Extensions to 2027-2041 in 70% of contracts (e.g., Leidos ERAM to 2041, Remote Medicine to 2026).
- ◆
Small/disadvantaged firms (40% of records, $1.7B) like Synergy, Kratos S2 with 80%+ outlays undervalued for M&A.
Sector Themes(3)
- ◆
Leidos/HII/Kratos/Salient capture $1.9B with 5-20 year terms in FAA/NASA/DHS R&D.
- ◆
Brasfield/Stronghold/North Wind win $670M firm-fixed for ports/parks/DOE sites, 80% outlaid.
- ◆
Leidos Biomed/Remote Medicine/HCBeck secure $1B+ for NCI/HIV/CDC through 2027.
Watch List(4)
- 👁
{"entity"=>"Leidos Holdings (LDOS)", "reason"=>"29% portfolio share ($1.27B obl, $7.7B ceiling) across agencies", "trigger"=>"Q1 2026 option exercises >$500M"}
- 👁
{"entity"=>"HII Mission Technologies (HII)", "reason"=>"$494M GSA with $860M options, $0 outlay signals ramp potential", "trigger"=>"outlays exceed $100M in H1 2026"}
- 👁
{"entity"=>"Brasfield & Gorrie", "reason"=>"$382M dual GSA wins in ports/courthouses, private construction proxy", "trigger"=>"follow-on PBS awards >$200M"}
- 👁
{"entity"=>"Kratos S2 (KTOS affiliate)", "reason"=>"$338M SBIR III defense R&D, 80% outlaid with commercialization upside", "trigger"=>"Phase III revenue recognition in FY26"}
Get daily alerts with 3 investment signals, 3 risk alerts, 3 opportunities and full AI analysis of all 15 filings
🇺🇸 More from United States
View all →March 25, 2026
US Pre-Market SEC Filings Roundup — March 25, 2026
US Pre-Market SEC Filings Roundup
March 24, 2026
US Merger & Acquisition SEC Filings — March 24, 2026
US Merger & Acquisition SEC Filings
March 24, 2026
US Corporate Board Director Changes SEC Filings — March 24, 2026
US Corporate Board Director Changes SEC Filings
March 24, 2026
US Executive Officer Management Changes SEC — March 24, 2026
US Executive Officer Management Changes SEC